DIADEMA PARTNERS LP
Long book
$242.2M
Q1 2026
Positions
86
Top-10 weight
50%
concentration
Last quarter
+16.9%
SPY +14.8%
Turnover
64%
of book per quarter
Strategy in plain words
auto-generated from filingsDIADEMA PARTNERS LP is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $242.2M US long book across 86 positions.
The portfolio is concentrated: the top 10 names carry 50% of the portfolio. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: BRIDGEBIO PHARMA INC, VIKING THERAPEUTICS INC, UNITED THERAPEUTICS CORP, JOHNSON & JOHNSON, COGENT BIOSCIENCES INC.
Over the last 6 quarters its long book ran on average 1.9pp per quarter ahead of the S&P 500, beating the index in 4 of 6 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-8.2%
Q1 2025
-3.8%
Q2 2025
+12.4%
Q3 2025
+19.8%
Q4 2025
+1.7%
Q1 2026
+16.9%
Sector allocation
Healthcare 95%
Other 5%
Long book by quarter
What does DIADEMA PARTNERS own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| VKTX VIKING THERAPEUTICS INC | Healthcare | 525.2K | $17.1M | 7.1% | +55.9% |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 27.3K | $16.2M | 6.7% | +173.0% |
| JNJ JOHNSON & JOHNSON | Healthcare | 53.8K | $13.1M | 5.4% | -19.1% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 322.8K | $12.4M | 5.1% | +144.8% |
| JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 54.8K | $10.4M | 4.3% | New |
| 430 TERNS PHARMACEUTICALS INC | — | 181.8K | $9.6M | 4.0% | -47.5% |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 148.2K | $8.4M | 3.5% | +1.3% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 80.9K | $7.9M | 3.2% | +118.5% |
| KOD KODIAK SCIENCES INC | Healthcare | 193.0K | $7.4M | 3.0% | New |
| INCY INCYTE CORP | Healthcare | 78.0K | $7.3M | 3.0% | New |
| TGTX TG THERAPEUTICS INC | Healthcare | 206.9K | $6.9M | 2.8% | +67.8% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 85.3K | $6.3M | 2.6% | +21.9% |
| LLY ELI LILLY & CO | Healthcare | 6.0K | $5.5M | 2.3% | +200.0% |
| ABBV ABBVIE INC | Healthcare | 24.1K | $5.2M | 2.2% | New |
| RCUS ARCUS BIOSCIENCES INC | Healthcare | 238.1K | $5.1M | 2.1% | New |
| CRBP CORBUS PHARMACEUTICALS HOLDI | Healthcare | 440.0K | $4.1M | 1.7% | New |
| CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 244.8K | $3.6M | 1.5% | New |
| ZYME ZYMEWORKS INC | Healthcare | 142.1K | $3.6M | 1.5% | New |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 187.3K | $3.1M | 1.3% | +200.7% |
| TENX TENAX THERAPEUTICS INC | Healthcare | 179.7K | $2.9M | 1.2% | -26.1% |
| HRMY HARMONY BIOSCIENCES HOLDINGS | Healthcare | 92.9K | $2.6M | 1.1% | +1138.2% |
| CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 78.9K | $2.4M | 1.0% | -50.1% |
| EYPT EYEPOINT INC | Healthcare | 178.5K | $2.3M | 1.0% | New |
| INDV INDIVIOR PHARMACEUTICALS INC | Healthcare | 71.4K | $2.2M | 0.9% | New |
| CLYM CLIMB BIO INC | Healthcare | 286.1K | $2.0M | 0.8% | New |
| STTK SHATTUCK LABS INC | Healthcare | 293.7K | $1.9M | 0.8% | New |
| TARS TARSUS PHARMACEUTICALS INC | Healthcare | 25.9K | $1.8M | 0.8% | New |
| ALKS ALKERMES PLC | Healthcare | 50.0K | $1.8M | 0.7% | New |
| MGNX MACROGENICS INC | Healthcare | 600.0K | $1.7M | 0.7% | New |
| VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 3.8K | $1.7M | 0.7% | -61.6% |
| VYGR VOYAGER THERAPEUTICS INC | Healthcare | 423.6K | $1.6M | 0.7% | New |
| PCVX VAXCYTE INC | Healthcare | 25.1K | $1.5M | 0.6% | +9.1% |
| RLMD RELMADA THERAPEUTICS INC | Healthcare | 200.8K | $1.4M | 0.6% | -48.4% |
| BIOA BIOAGE LABS INC | Healthcare | 60.0K | $1.0M | 0.4% | -77.9% |
| INO INOVIO PHARMACEUTICALS INC | Healthcare | 562.7K | $979K | 0.4% | +5.4% |
| AYTU AYTU BIOPHARMA INC | Healthcare | 353.1K | $964K | 0.4% | +15.5% |
| EQ EQUILLIUM INC | Healthcare | 433.8K | $868K | 0.4% | +24.9% |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 10.0K | $839K | 0.3% | New |
| PHVS PHARVARIS NV | Healthcare | 29.3K | $828K | 0.3% | New |
| ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 65.0K | $820K | 0.3% | -0.3% |
| REPL REPLIMUNE GROUP INC | Healthcare | 100.7K | $770K | 0.3% | -56.4% |
| XERS XERIS BIOPHARMA HOLDINGS INC | Healthcare | 132.7K | $770K | 0.3% | -22.2% |
| LRMR LARIMAR THERAPEUTICS INC | Healthcare | 166.6K | $750K | 0.3% | New |
| ANNX ANNEXON INC | Healthcare | 132.9K | $736K | 0.3% | -62.0% |
| RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 35.1K | $736K | 0.3% | New |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 26.3K | $714K | 0.3% | +5.4% |
| UNCY UNICYCIVE THERAPEUTICS INC | Healthcare | 106.1K | $698K | 0.3% | New |
| SPRB SPRUCE BIOSCIENCES INC | Healthcare | 10.0K | $654K | 0.3% | New |
| PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 54.6K | $607K | 0.3% | New |
| CELC CELCUITY INC | Healthcare | 5.3K | $607K | 0.3% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 144 | $587.7M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 145 | $580.5M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 130 | $391.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 96 | $328.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 102 | $383.3M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 107 | $233.1M | canonical | SEC ↗ |